GlassScriptPhysician profile
Leslie Ann Lattin
NPI 1194275099
$7,926.71
in general payments reported to CMS, 2019-2025
41 companies · $1,542 in 2025
The $1,542 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,633 · 2022: $1,832 · 2023: $1,372 · 2024: $1,548 · 2025: $1,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,462.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,271.16 | 2021-2025 | |
| Novo Nordisk INC | $978.82 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $846.88 | 2021-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $592.08 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $544.06 | 2021-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $497.53 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $424.29 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $309.00 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $237.31 | 2022-2025 | |
| Abbott Laboratories | $196.98 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.63 | 2021-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $184.86 | 2021 | |
| Boston Scientific Corporation | $172.83 | 2022-2025 | General - Pain Management, Watchman Access System |
| Sanofi-Aventis U.S. LLC | $170.61 | 2021-2023 | |
| Daiichi Sankyo INC. | $139.94 | 2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Lattin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.